Wouldn't it be great if we could do that more systematically? Could we, in fact, (1) _____ all the companies that are out there that have drugs in their (2) _____ that are known to be safe in humans but have never actually succeeded in terms of being effective for the (3) _____ they were tried for? Now we're learning about all these new molecular pathways -- some of those could be repositioned or repurposed, or whatever word you want to use, for new applications, basically teaching old drugs new tricks. That could be a phenomenal, valuable activity. We have many (4) ______ now between NIH and companies about doing this that are looking very (5) ______. And you could expect quite a lot to come from this. There are quite a number of success stories one can point to about how this has led to major (6) ______. The first drug for HIV/AIDS was not developed for HIV/AIDS. It was developed for cancer. It was AZT. It didn't work very well for cancer, but became the first successful antiretroviral, and you can see from the table there are others as well. So how do we actually make that a more generalizable effort? Well, we have to come up with a partnership between academia, government, the private (7) ______, and patient organizations to make that so. At NIH, we have started this new National Center for Advancing Translational Sciences. It just started last December, and this is one of its (8) ______.